In part two of this two-part series, several experts from a DIA panel share additional insights around the types of differentiation biosimilar companies can pursue and its overall impact on product/device selection and the manufacturing process.
- IQVIA’s U.S. Biosimilar Report: Your Most Pressing Questions Answered
- Interacting With FDA During Biosimilar Development: From Initial Advisory Meeting To BLA
- The Little-Known Drivers Behind 2020’s (And 2021’s?) Biosimilar Boom
- Mapping The Development Of A Biosimilar Candidate: Analytical & Regulatory Decisions
- Mammalian Biomanufacturing Industry Supply & Demand Trends
- Federal Circuit To Decide Limits On Functional Claiming Of Isolated Monoclonal Antibodies
- Biosimilars: The New World Of Commercialization
Mammalian Biomanufacturing Industry Supply & Demand Trends
While capacity will increase over the next five years, demand for capacity, pandemic aside, will increase at a slightly faster rate, allowing for some short-term loosening of capacity constraints, but after 2024, capacity tightening may occur.
Federal Circuit To Decide Limits On Functional Claiming Of Isolated Monoclonal Antibodies
Can a patent claim millions of different antibodies based on their function alone? Tens of thousands? Hundreds? What if the patent gives a plug-and-play road map to make and evaluate the antibodies through routine testing? Whatever the CAFC’s answer, one thing is sure: It will affect how biologic innovators use functional claiming and whether patentees or challengers are more likely to win future lawsuits in the biologics and biosimilar arena.
Biosimilars: The New World Of Commercialization
Great changes are afoot in the world of biosimilar commercialization. Here, Abraxeolus Consulting manager Edric Engert walks you through his view as to what has been, what has changed, and what the new flexible biosimilar business model of the future will look like.
Private Equity: A New Pillar For Biosimilar Development?
The emergence of the biosimilar market represents an interesting opportunity for private equity firms in the global healthcare landscape. Here are the biggest deals from the last two years that suggest there is growing willingness outside of government funding to invest in biosimilar development — especially in emerging markets.
Weighing The Potential Of Humira Biosimilars In The U.S. — Expected Winners And Losers
This is the second article in a two-part series exploring the anticipated competitive landscape for Humira (adalimumab) biosimilars following their U.S. launch in 2023. In this part, we evaluate the potential for individual adalimumab biosimilar products, comparing and contrasting the agents based on a number of important factors, including order of market entry, company resources and reputation, and product characteristics.
Weighing The Potential Of Humira Biosimilars In The U.S.
This two-part article series explores the factors differentiating the Humira (adalimumab) biosimilar market from that of infliximab biosimilars, which could lead to stronger uptake of these products in the U.S. In Part 1, we focus on the unique competitive dynamics within the adalimumab biosimilar market.
FDA Releases Guidance On Normal GMP Operations During COVID-19
Most FDA guidance on COVID has been associated with tools to combat the pandemic. This new guidance should be read by all drug and biologic manufacturers, whether or not they produce COVID-related products.
BIOSIMILAR WHITE PAPERS
Counting DNA Molecule By Molecule
Digital PCR is an established nucleic acid (NA) quantification technology, which enhances the broad use of PCR across molecular biology laboratories globally through improved precision and accuracy. Organizations that impact the quality of nucleic acid measurement and testing, adopted digital PCR early on and have since been pioneering its use for improved accuracy and precision in NA measurement. Ultimately, this will positively impact the quality of NA measurements generally and, more specifically, clinical NA testing. Molecular counting of nucleic acid molecules is the next measurement paradigm.
ICH Q12 Updates: Increasing Efficiency Of Post-Approval Changes
Through proper implementation of ICH Q12 tools and enablers, the industry could manage CMC changes effectively under a company’s pharma quality system with less need for oversight prior to implementation.
Mechanistic Modeling Of Chromatography To Speed Up Process Development
Catch up on the current opportunities and challenges for using mechanistic modeling to simulate and predict chromatographic behavior and experiments in silico.
Considerations for improving outcome in biopharmaceutical process development
In this article, we take a look at how the biopharmaceutical process outcome can be improved by increasing the performance and robustness of the bioprocess workflow through a variety of critical aspects, different strategic approaches, and innovative tools and methods.
6 Regulatory Changes Affecting Bioprocessing In China
This article outlines six recent regulatory changes in China intended to protect patient safety as well as reduce regulatory burdens and minimize delays.
Sensitive And Reproducible SPR-Based Concentration And Ligand-Binding Analyses
Surface plasmon resonance (SPR) assays are used across the life cycle of a biopharmaceutical, from target identification, through CQA determination, development, and on-going quality control. This article focuses on concentration assays associated with late-stage development and biotherapeutic drug chemical manufacturing and control.
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
LIFE SCIENCE EVENTS
Outlook - Master Your Mailbox - Inbox Hero Inbox Zero
November 24, 2020
BREXIT - What's Changing for Life Science Product License Holders-Manufacturers and What you Need to do Right Now
December 1, 2020
Physician Compensation Update: What Providers Need to Know
December 1, 2020
HIPAA HITECH Changes 2021 - What's New?
December 2, 2020
Data Integrity: Compliance with 21 CFR Part 11, SaaS-Cloud, EU GDPR
December 3, 2020